Defective anticarbohydrate antibody responses to naturally occurring bacteria following bone marrow transplantation.
The long-term recipients of allogeneic bone marrow transplantation (BMT) are at an increased risk of death due to bacterial infections. We evaluated the anticarbohydrate antibody responses of BMT recipients to a naturally occurring bacterial carbohydrate, polyribose phosphate (PRP). The recipients of autologous BMT achieved protective anti-PRP levels (>100 ng/mL) by 3 years after transplantation, with a pattern consistent with a recapitulation of the ontogeny of anticarbohydrate antibody responses. None of the six recipients of unrelated BMT who were off immunosuppressive therapy had protective anti-PRP levels, though their response to a protein antigen (tetanus toxoid) was normal. Of 48 recipients of histocompatible BMT, 22 (46%) had protective anti-PRP antibody levels, whereas 13 (27%) recipients who were >3 years post-BMT did not have protective levels. Therefore, all unrelated recipients and a significant proportion of histocompatible recipients without clinical graft-vs.-host disease had persistent and prolonged defects in their capacity to produce antibodies to naturally occurring bacterial carbohydrate antigens. These results suggest that allogeneic BMT recipients should be longitudinally evaluated for their anticarbohydrate antibody responses and that patients with defective antibody responses should receive prophylactic antibiotics or replacement immunoglobulin therapy or both to reduce their risk of late bacterial infections.
Kapoor
N
N
Division of Research Immunology/Bone Marrow Transplantation, Children's Hospital-Los Angeles, CA 90027, USA.
Chan
R
R
Weinberg
K I
KI
Burotto
F
F
Parkman
R
R
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation; D001424:Bacterial Infections / Q000276:immunology*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D016014:Linear Models; D009894:Opportunistic Infections / Q000276:immunology*; D010428:Pentosephosphates / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D010428:Pentosephosphates; D011135:Polysaccharides, Bacterial; C003191:polyribose phosphate